Document is current

Any future updates will be listed below

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

Crossref DOI link: https://doi.org/10.1186/s12885-015-1685-z

Published Online: 2015-10-14

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark